A heat-resistant β-1,3-glucanase mutant and its application

By performing a double-point mutation of H203L/Q81D on β-1,3-glucanase, the catalytic activity and thermal stability of the enzyme were improved, solving the problems of low enzymatic hydrolysis efficiency and insufficient thermal stability in the existing technology, and realizing the efficient production of β-glucan oligosaccharides.

CN123063380APending Publication Date: 2026-11-10SHANGHAI UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202611291596.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-25
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing GH16 family β-1,3-glucanases have shortcomings in catalytic activity and thermal stability, resulting in low enzymatic hydrolysis efficiency and high production costs, which limits their industrial application.

Method used

By performing site-directed mutagenesis on the amino acid sequence of wild-type β-1,3-glucanase, specifically by mutating histidine (H) at position 203 to leucine (L) and glutamine (Q) at position 81 to aspartic acid (D), combined with sequence consistency analysis and surface charge distribution analysis, a β-1,3-glucanase mutant with synergistically enhanced catalytic activity and thermal stability was obtained.

Benefits of technology

The catalytic activity of β-1,3-glucanase was increased by 21.8% and the thermal stability was extended by about 2.5 times. The mutant had a half-life of 56.7 minutes at 70°C, making it suitable for the efficient enzymatic production of β-glucan oligosaccharides.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063380A_ABST
    Figure CN123063380A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of enzyme engineering technology and relates to a thermostable β-1,3-glucanase mutant and its applications. The three-dimensional structure of the SlGlc16a protein was determined through homology modeling and molecular docking. Combined with sequence consistency analysis and surface charge distribution analysis, key mutation sites were screened. Through site-directed mutagenesis and combinatorial mutagenesis, a double-site mutant H203L / Q81D was obtained, which is the thermostable β-1,3-glucanase mutant of this application. The gene encoding the mutant, the recombinant expression vector, the genetically engineered bacteria, and its application in the preparation of β-glucan oligosaccharides are also disclosed. Compared with wild-type β-1,3-glucanase, the specific enzyme activity of the mutant of this invention increased from 4862.6 U / mg to 5922.6 U / mg, and the half-life at 70°C was extended from 23.0 min to 56.7 min, achieving a synergistic improvement in catalytic activity and thermal stability, showing good application prospects in the field of industrial biocatalysis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of enzyme engineering technology and relates to a heat-resistant β-1,3-glucanase mutant and its application, specifically a mutant β-1,3-glucanase with improved thermal stability and catalytic activity. Background Technology

[0002] β-1,3-glucan is a class of macromolecular polysaccharides whose backbone is composed of glucose polymerized via β-1,3-glycosidic bonds. It is widely found in bacterial cell walls, fungal cell walls, and plant tissues. Natural β-1,3-glucan, depending on its source, typically also contains β-1,6-glycosidic side chains of varying sizes and proportions. β-1,3-glucan possesses a variety of significant physiological activities, including immunomodulation, anti-tumor, anti-inflammatory, anti-aging, and regulation of blood glucose and lipids. However, the large molecular weight and poor water solubility of natural β-1,3-glucan severely limit its full potential for biological activity and its practical application in functional foods, pharmaceuticals, and other fields.

[0003] β-glucan oligosaccharides are enzymatic degradation products of β-1,3-glucan, characterized by low molecular weight, high water solubility, and easy absorption and utilization by the human body. Studies have shown that β-glucan oligosaccharides have various effects, including enhancing immunity, promoting gut microbiota balance, improving nutrient absorption, preventing tooth decay, and lowering cholesterol. Furthermore, β-glucan oligosaccharides possess significant advantages such as low digestibility, low calorie content, and safety and stability, making them a class of water-soluble functional oligosaccharides with high development and utilization value. β-glucan oligosaccharides show broad application prospects in functional foods, health products, and pharmaceuticals. However, the current high production cost of β-glucan oligosaccharides severely limits their large-scale application and market promotion.

[0004] β-1,3-glucanase (EC 3.2.1.39) is a class of glycosidic hydrolases that specifically hydrolyze β-1,3-glycosidic bonds. According to the Carbohydrate Active Enzyme Database (CAZy), β-1,3-glucanases mainly belong to the GH16, GH17, and GH55 families. The GH16 family is an important source of β-1,3-glucanases, and its members are highly conserved in bacteria and fungi. GH16 family β-glucanases primarily act on β-linked glycan substrates via endocleavage. Currently, GH16 family β-1,3-glucanases have demonstrated significant application value in grain processing, beer brewing, animal feed, and the preparation of functional oligosaccharides.

[0005] However, most of the GH16 family β-1,3-glucanases reported so far still face many limitations in practical applications. On the one hand, their catalytic activity is generally low, resulting in low enzymatic hydrolysis efficiency and high production costs; on the other hand, their thermal stability is insufficient, and they are easily inactivated under the high-temperature reaction conditions required for industrial catalysis, which seriously restricts their industrial application. Although some studies have attempted to improve the thermal stability and catalytic efficiency of β-glucanases through protein engineering, such as the β-1,3-glucanase mutant disclosed in patent CN120505298A, which shows that the enzyme activity of the β-1,3-glucanase mutant constructed by this invention is 1.04 to 1.81 times higher than that of the wild-type enzyme, and the Tm value is increased by 0.97 to 1.19 °C, the half-life at 70 °C is only increased by 1.08 to 1.28 times, and the improvement in thermal stability is relatively limited. In addition, only single-point mutations are considered.

[0006] However, how to achieve a synergistic improvement in catalytic activity and thermal stability while maintaining the original excellent enzymatic properties of the enzyme remains a technical challenge that urgently needs to be solved in this field. Summary of the Invention

[0007] The purpose of this invention is to address the technical bottleneck of the difficulty in synergistically improving the catalytic activity and thermal stability of existing β-1,3-glucanases, and to provide a high-temperature resistant β-1,3-glucanase mutant and its application, which maintains the original excellent enzymatic properties of the enzyme while achieving a synergistic improvement in catalytic activity and thermal stability.

[0008] The objective of this invention can be achieved through the following technical solutions: One of the technical solutions of the present invention is to provide a β-1,3-glucanase mutant.

[0009] In some embodiments of the present invention, the β-1,3-glucanase mutant is obtained by mutating histidine (H) at position 203 of the wild-type β-1,3-glucanase, as shown in SEQ ID NO.1, to leucine (L), and glutamine (Q) at position 81 to aspartic acid (D).

[0010] In some preferred embodiments of the present invention, the amino acid sequence of the β-1,3-glucanase mutant is shown in SEQ ID NO.3.

[0011] In some embodiments of the present invention, the wild-type β-1,3-glucanase SlGlc16a described herein is derived from Shouchella lehensis G1, which belongs to the GH16 family and consists of 261 amino acids, the amino acid sequence of which is shown in SEQ ID NO.1 and the gene sequence of which is shown in SEQ ID NO.2.

[0012] The method for obtaining the β-1,3-glucanase mutant described in this invention is conventional in the art: preferably, the three-dimensional structure of β-1,3-glucanase is determined by homology modeling and molecular docking, and key mutation sites are screened by sequence consistency analysis and surface charge distribution analysis. Site-directed and combined mutations of wild-type β-1,3-glucanase were performed. It was found that mutating histidine (H) at position 203 of the wild-type β-1,3-glucanase (as shown in SEQ ID NO.1) to leucine (L) and glutamine (Q) at position 81 to aspartic acid (D) yielded a double-site mutant H203L / Q81D with synergistically enhanced catalytic activity and thermostability. The amino acid sequence of the mutant is shown in SEQ ID NO.3. In addition, replacing other amino acid residues in the amino acid sequence shown in SEQ ID NO.1 with other amino acid residues that do not affect the catalytic performance of the β-1,3-glucanase mutant is also within the scope of this invention.

[0013] The second technical solution of the present invention is to provide an isolated nucleic acid.

[0014] The nucleic acid is a DNA molecule encoding the β-1,3-glucanase mutant.

[0015] In some embodiments of the present invention, the gene sequence encoding the β-1,3-glucanase mutant is shown in SEQ ID NO.4.

[0016] The method for obtaining the encoding nucleic acid of the β-1,3-glucanase mutant described in this invention is conventional in the art: preferably, the known nucleotide sequence encoding the β-1,3-glucanase mutant, such as SEQ ID NO.4, is synthesized artificially as a complete sequence, or the mutant site is introduced into the wild-type β-1,3-glucanase gene by using overlap extension PCR or full plasmid large primer PCR.

[0017] The third technical solution of the present invention is to provide a recombinant expression vector, wherein the recombinant expression vector comprises a DNA molecule encoding the above-mentioned β-1,3-glucanase mutant.

[0018] In some embodiments of the present invention, the recombinant expression vector can be constructed by connecting the coding nucleic acid sequence of the β-1,3-glucanase mutant gene of the present invention to various suitable vectors using conventional methods in the art. The vector can be any conventional vector in the art, preferably a pET series vector, and more preferably a pET-28a plasmid.

[0019] Preferably, the recombinant expression vector of the present invention can be prepared by the following method: the gene sequence DNA fragment of the β-1,3-glucanase mutant obtained by overlap extension PCR and the empty vector plasmid pET-28a are digested with restriction endonucleases PstⅠ and BamHI, the digested β-1,3-glucanase mutant gene sequence DNA fragment and the empty vector plasmid pET-28a are recovered, and ligated using T4 DNA ligase to construct a recombinant expression vector containing the coding nucleic acid sequence of β-1,3-glucanase.

[0020] The fourth technical solution of the present invention is to provide a recombinant expression transformant comprising the above-mentioned recombinant expression vector.

[0021] In some embodiments of the present invention, the host cell of the recombinant expression transformant is Escherichia coli.

[0022] In some preferred embodiments of the present invention, the host cell is Escherichia coli BL21(DE3).

[0023] The recombinant expression transformant can be prepared by introducing the recombinant expression vector of the present invention into host cells using conventional methods in the art. The host cell is a conventional host cell in the art, provided that the recombinant expression vector can stably replicate spontaneously and that the nucleic acid sequence encoding the β-1,3-glucanase mutant carried by it can be effectively expressed; preferably, it is *Escherichia coli*, more preferably *Escherichia coli* BL21(DE3). Transforming the recombinant expression vector into *Escherichia coli* BL21(DE3) yields the preferred genetically engineered strain of the present invention.

[0024] The fifth technical solution of the present invention is: to provide a β-1,3-glucanase catalyst, characterized in that the β-1,3-glucanase catalyst comprises any one of the following forms: (1) Culture the recombinant expression transformant and isolate the transformant cells containing the β-1,3-glucanase mutant; (2) Cultivate the recombinant expression transformant and isolate the crude enzyme solution containing the β-1,3-glucanase mutant; (3) Cultivate the recombinant expression transformant, separate the crude enzyme solution containing the β-1,3-glucanase mutant, and freeze-dry the crude enzyme powder obtained; (4) Cultivate the recombinant expression transformant, separate the crude enzyme solution containing the β-1,3-glucanase mutant, and purify the obtained pure enzyme solution.

[0025] In some embodiments, the method for culturing the recombinant expression transformant may include the following steps: culturing the recombinant expression transformant of the present invention to obtain a recombinant β-1,3-glucanase mutant. For recombinant *E. coli*, a preferred culturing method is as follows: the recombinant *E. coli* constructed as described above is inoculated into LB medium containing kanamycin (50 μg / mL) and activated overnight at 37°C and 180 rpm. Then, it is transferred at a 1% inoculum to fresh LB medium containing kanamycin (50 μg / mL) and cultured at 37°C and 180 rpm until the OD600 reaches 0.6-0.8. IPTG is then added to a final concentration of 1 mM, and the culture is induced at 30°C and 200 rpm for 12 h. After fermentation, the bacterial precipitate was collected by centrifugation at 10000×g for 10 min at 4℃. The precipitate was resuspended in buffer A (29.25 g NaCl, 2.42 g Tris-HCl, 1.36 g imidazole, brought to a final volume of 1 L, and pH adjusted to 7.9). The precipitate was then sonicated in an ice-water bath (30% power, on for 2.2 s, off for 3.3 s) for 10 min, centrifuged at 10000×g for 15 min at 4℃, and the supernatant was collected as the crude enzyme solution.

[0026] The sixth technical solution of the present invention is: to provide a method for preparing a β-1,3-glucanase mutant.

[0027] In some embodiments of the present invention, the preparation method includes the following steps: (1) Provide a DNA molecule encoding the above-mentioned β-1,3-glucanase mutant; (2) The DNA molecule is cloned into an expression vector to construct a recombinant expression vector; (3) The recombinant expression vector is transformed into host cells to obtain recombinant engineered bacteria; (4) Cultivate the recombinant engineered bacteria, induce expression, and collect and purify the β-1,3-glucanase mutant.

[0028] The seventh technical solution of the present invention is: to provide an application of a β-1,3-glucanase catalyst in the degradation of β-1,3-glucan to prepare β-glucan oligosaccharides.

[0029] In some embodiments of the present invention, the β-1,3-glucan comprises kelp polysaccharide and / or laminarin. When the β-1,3-glucan is selected as kelp polysaccharide, the β-glucan oligosaccharide is a β-glucan oligosaccharide with a degree of polymerization of 2-6.

[0030] The β-1,3-glucanase mutant of the present invention is an endonuclease, which can specifically hydrolyze β-1,3-glycosidic bonds, but cannot hydrolyze α-1,6-glycosidic bonds or β-1,4-glycosidic bonds.

[0031] Compared with the prior art, the present invention has the following advantages: (1) This invention uses a semi-rational design strategy, combined with sequence consistency analysis and surface charge distribution analysis, to screen and verify the synergistic effect of H203L and Q81D sites on thermal stability and catalytic activity in SlGlc16a protein.

[0032] (2) The specific enzyme activity of the two-point mutant H203L / Q81D (SlGlc16aM2) provided by the present invention reached 5922.6 U / mg, which was 21.8% higher than that of the wild type (4862.6 U / mg); the half-life at 70℃ reached 56.7 min, which was about 2.5 times longer than that of the wild type (23.0 min), achieving a significant synergistic improvement in catalytic activity and thermal stability.

[0033] (3) The mutant of the present invention is an endonuclease, which can efficiently hydrolyze β-1,3-glycosidic bonds. It has high hydrolytic activity for keratin polysaccharide (a linear polysaccharide containing only β-1,3-glycosidic bonds) and laminarin polysaccharide (the main chain is β-1,3-glycosidic bonds and the side chain contains β-1,6-branchings). It can be applied to the enzymatic production of β-glucan oligosaccharides. Attached Figure Description

[0034] Figure 1 Molecular docking diagram for predicting β-1,3-glucanase SlGlc16a with substrate β-1,3-glucan; Figure 2 The plasmid contains the recombinant β-glucanase SlGlc16a gene; Figure 3 Design for mutation sites based on sequence consistency; Figure 4 The results of the initial screening for the thermostability and specific activity of the mutants; Figure 5 This serves as an initial screening for potential high thermal stability mutants. Figure 6 The half-life (A) and optimal reaction temperature (B) of the combined mutant at 70°C are given. Figure 7 Thin-layer chromatography results for the hydrolysis products of SlGlc16aM2. Detailed Implementation

[0035] The present invention will now be described in detail with reference to specific embodiments. Those skilled in the art should understand that the following embodiments are for illustrative purposes only and should not be considered as limiting the scope of the invention. Any modifications or substitutions made to the methods, steps, or conditions of the present invention without departing from the spirit and substance of the invention are within the scope of the invention.

[0036] Unless otherwise specified, the experimental methods used in the following examples are conventional methods; and the materials and reagents used are commercially available unless otherwise specified.

[0037] Example 1: Obtaining β-1,3-glucanase SlGlc16a and semi-rational design of mutation sites 1.1 Obtaining wild-type SlGlc16a The wild-type β-1,3-glucanase used in this invention is derived from Shouchella lehensis G1, named SlGlc16a, has the amino acid sequence shown in SEQ ID NO.1 and the gene sequence shown in SEQ ID NO.2. Its GenBank accession number is AIC93282.1.

[0038] The SlGlc16a gene was cloned into the expression vector pET-28a using homologous recombination to construct a recombinant plasmid, such as... Figure 2 As shown, the protein was transformed into Escherichia coli BL21(DE3), and after IPTG induction and Ni-NTA affinity chromatography purification, recombinant wild-type SlGlc16a protein was obtained.

[0039] Molecular docking diagrams of β-1,3-glucanase SlGlc16a and its substrate β-1,3-glucan were predicted using homology modeling and molecular docking, as shown below. Figure 1 As shown.

[0040] 1.2 Semi-rational design of mutation sites (1) Sequence identity analysis: Multiple sequence alignment and sequence identity analysis were performed on homologous proteins of the GH17 family β-1,3-glucanase using the online tool Consensus Finder. Based on an identity value higher than 40%, eight candidate mutation sites were screened: S56T, H203L, A169G, E164N, N43Y, I207Q, Q81D, and A180F. Figure 3 As shown.

[0041] (2) Surface charge analysis: The relative solvent accessibility of amino acid residues in the SlGlc16a protein was analyzed using the online analysis tools NetSurf P-3.0 and E-pRSA. The standard for exposed residues was a relative solvent accessibility greater than 0.5. At the same time, the conserved sites were excluded by combining the online tool Consurf. The uncharged glutamine (Q) and asparagine (N) exposed on the surface were selected to be mutated to negatively charged glutamic acid (E) and aspartic acid (D), respectively. Ten candidate mutation sites were screened: N66D, N26D, N240D, N43D, N16D, Q81E, Q75E, Q5E, Q129E and Q166E.

[0042] (3) Combinatorial Mutation Design: Based on the screening results of the above two strategies, after preliminary evaluation of the thermal stability and catalytic activity of single-site mutants, the three dominant sites Q81D, Q129E and H203L were selected for iterative combination mutation, and the following four combination mutants were constructed: SlGlc16aM1 (Q81D-Q129E) SlGlc16aM2 (Q81D-H203L) SlGlc16aM3 (Q129E-H203L) SlGlc16aM4 (Q81D-Q129E-H203L) Example 2 Construction, expression and purification of mutants 2.1 Site-directed mutation Using the plasmid pET-28a-SlGlc16a containing the wild-type SlGlc16a gene as a template, site-directed mutagenesis was introduced using overlap extension PCR. Upstream and downstream primers containing the mutation site were designed, and their sequences are shown in Table 2.

[0043] The PCR reaction system is shown in Table 1 below: Table 1 PCR reaction system (25 μL) The PCR amplification conditions were as follows: 95℃ pre-denaturation for 2 min; 95℃ denaturation for 20 s, 55-65℃ annealing for 20 s (adjusted according to primer Tm value), 72℃ extension for 2 min, for 25 cycles; and finally 72℃ extension for 5 min.

[0044] After verification by agarose gel electrophoresis, the PCR products were digested with restriction endonuclease Dpn I (1 μL) at 37°C for 1–2 h, followed by inactivation at 80°C for 20 min. 5 μL of the digested product was transformed into *E. coli* DH5α, plated on LB agar plates containing kanamycin (50 μg / mL), and incubated overnight at 37°C. Single colonies were picked for colony PCR verification and then sequenced for confirmation.

[0045] The upstream and downstream primers are changed according to the different amino acid mutation sites introduced. The specific primer sequences are shown in Table 2.

[0046] Table 2 Primer sequences for site-directed mutagenesis 2.2 Expression and purification of mutants The mutant plasmid, which was verified to be correct by sequencing, was transformed into Escherichia coli BL21(DE3) to obtain a strain expressing the mutant protein.

[0047] The recombinant engineered strain was inoculated into LB medium containing kanamycin (50 μg / mL) and activated overnight at 37°C and 180 rpm. Then, it was transferred to fresh LB medium containing kanamycin (50 μg / mL) at a 1% inoculation rate and cultured at 37°C and 180 rpm until the OD600 reached 0.6-0.8. IPTG was then added to a final concentration of 1 mM, and the culture was induced at 30°C and 200 rpm for 12 h.

[0048] After fermentation, the bacterial precipitate was collected by centrifugation at 10000×g for 10 min at 4℃. The precipitate was resuspended in buffer A (29.25 g NaCl, 2.42 g Tris-HCl, 1.36 g imidazole, brought to a final volume of 1 L, and pH adjusted to 7.9). The precipitate was then sonicated in an ice-water bath (30% power, on for 2.2 s, off for 3.3 s) for 10 min, centrifuged at 10000×g for 15 min at 4℃, and the supernatant was collected as the crude enzyme solution.

[0049] Affinity chromatography purification was performed using Ni Sepharose 6 Fast Flow column stock. Washing and elution were performed using buffer A and buffer B (29.25 g NaCl, 2.42 g Tris-HCl, 13.62 g imidazole, adjusted to 1 L, pH 7.9). Elution fractions with OD280 > 0.6 were collected, dialyzed overnight, and stored at 4°C for later use. The purity of the purified protein was determined by SDS-PAGE.

[0050] Example 3 Characterization of the enzymatic properties of the mutant 3.1 Determination of enzyme activity and specific enzyme activity The enzyme activity of β-1,3-glucanase was characterized by detecting the reducing sugar content using the 3,5-dinitrosalicylic acid (DNS) method. A standard curve was plotted using glucose as the standard.

[0051] (1) Construction of glucose standard curve: Prepare an anhydrous glucose standard solution with a concentration of 1 mg / mL. Take 7 EP tubes and number them 06. Add 0, 10, 20, 40, 60, 80 and 100 μL of glucose standard solution to each tube respectively. Then add distilled water to make the total liquid volume of each tube 400 μL. Then add 800 μL of DNS reagent to each tube. After mixing thoroughly, place it in a boiling water bath and heat accurately for 10 min for color development. After taking it out, immediately cool it to room temperature with running water. Use tube 0 as a blank to zero the instrument. Measure the absorbance of each tube at a wavelength of 540 nm. Perform linear regression with glucose concentration as the abscissa and absorbance value as the ordinate to draw the glucose standard curve and obtain the regression equation.

[0052] (2) Enzyme activity assay: Add 50 μL of appropriately diluted enzyme solution to 350 μL of 4% (w / v) colloidal kodanose (50 mM citrate-disodium hydrogen phosphate buffer, pH 4.5), and react precisely at 65℃ for 10 min. After the reaction, add 800 μL of DNS reagent and boil in a water bath for 10 min for color development. After cooling, centrifuge at 10000×g for 10 min and measure the OD540 value of the supernatant. Calculate the amount of reducing sugar generated according to the standard curve. Use ultrapure water instead of enzyme solution as a blank control. Each experiment should have at least three replicates. Results are expressed as mean ± standard deviation.

[0053] (3) The Bradford method was used to determine the protein concentration. Bovine serum albumin (BSA) was used as the standard. The absorbance was measured at 595 nm to prepare a standard curve and calculate the protein concentration of the sample.

[0054] (4) Specific enzyme activity is defined as the amount of enzyme required to release 1 μmol of glucose equivalent reducing sugar per minute by hydrolyzing polysaccharides at pH 6.5 and 65℃. Specific enzyme activity is expressed as U / mg protein. The specific enzyme activity of β-1,3-glucanase is calculated using the following formula: Specific vitality U=C×V 总 ×n / M×t×m 酶 In the formula, C is the mass of reducing sugar (glucose equivalent) generated in the reaction system obtained from the DNS standard curve, in mg; V 总 n is the total volume of the reaction system after DNS color development, in mL; n is the enzyme dilution factor; M is the molar mass of glucose, M = 180.16 g / mol; t is the enzyme-catalyzed reaction time, in min; m 酶 The amount of enzyme solution added is in mg.

[0055] 3.2 Initial screening of thermal stability and determination of half-life To rapidly screen mutants with improved thermostability, the purified single-point mutant enzyme solutions were incubated at 70℃ for 30 min, followed by measurement of residual enzyme activity. Untreated enzyme solutions served as controls. Results are as follows: Figure 4 As shown, after initial screening, some mutants designed according to the above two methods were found to have application potential: the residual activity of mutants Q81D, Q129E and H203L was higher than that of the original protein; while the relative activity of mutant N26D was significantly higher than that of the original protein.

[0056] The thermal stability of the above four mutants was further investigated, and the half-life determination results are as follows: Figure 5As shown, the original protein has a half-life of 23.0 min at 70℃, while the mutant N26D, which has a significantly increased enzyme activity, has a half-life of only 20.7 min, and its activity is basically lost after 1 h of high-temperature treatment. In addition, the half-lives of mutants Q81D, Q129E, and H203L are 42.2, 40.9, and 46.3 min, respectively, which are significantly higher than those of the original protein, indicating that their thermostability is improved. At the same time, the residual activity of mutants Q81D and H203L during the monitoring process is higher than that of the original protein, indicating that they have certain potential for industrial application.

[0057] The mutants Q81D, Q129E, and H203L, which exhibit significantly improved thermal stability, were subjected to iterative combined mutagenesis to obtain mutants with even better properties. Therefore, three two-point combined mutagenesis and one three-point combined mutagenesis were designed, and the mutants were named M1 (Q81D-Q129E), M2 (Q81D-H203L), M3 (Q129E-H203L), and M4 (Q81D-Q129E-H203L), respectively. The half-lives and optimal reaction temperatures of the four combined mutagenesis were determined, and the results are as follows: Figure 6 As shown, among the four combined mutations, M2 has the longest half-life at 70℃, reaching 56.7 min, while the half-lives of M1, M3, and M4 are 51.9, 53.1, and 50.9 min, respectively. The results of the optimal reaction temperature determination show that the optimal reaction temperature of M1 and M2 increased by 10℃, while the optimal reaction temperature of M3 and M4 increased by 5℃. The experimental results indicate that the thermal stability of the four combined mutations has been greatly improved.

[0058] Therefore, the results of the combined mutation showed that SlGlc16aM2 (Q81D-H203L) exhibited the best thermal stability, with a half-life (56.7 min) that was significantly longer than that of the wild type (23.0 min).

[0059] 3.3 Optimal reaction temperature and pH Following the method in Example 3.1, enzyme activity was measured at 30-70°C (5°C intervals), and relative enzyme activity was calculated with the highest enzyme activity as 100%.

[0060] The optimal reaction temperature for SlGlc16aM2 is 65℃, which is 5℃ higher than that of the wild type (60℃). At 65℃, the relative enzyme activity of SlGlc16aM2 reaches 100%.

[0061] 4% (w / v) colloidal kodanose was prepared using buffers with different pH values ​​(50 mM citrate-disodium hydrogen phosphate buffer, pH 3.0-7.0; 50 mM acetate-sodium acetate buffer, pH 4.5-5.5; 50 mM Tris-HCl buffer, pH 7.0-9.0), and enzyme activity was determined at 65°C. The optimal reaction pH for SlGlc16aM2 was 6.5.

[0062] 3.4 Comparison of enzymatic properties between wild type and mutant The specific enzyme activity, optimal temperature, optimal pH, and half-life at 70°C of wild-type SlGlc16a and SlGlc16aM2 were determined according to the method in Example 3.1, and the results are shown in Table 2.

[0063] Table 2 Enzymatic properties of wild-type SlGlc16a and its mutant SlGlc16aM2 The results showed that, compared with the wild type, the mutant SlGlc16aM2 had an increased specific enzyme activity of about 21.8%, an increased optimum temperature of 5 °C, and a half-life of about 2.5 times longer at 70 °C.

[0064] 3.5 Substrate Specificity The specific enzyme activities of kerogen polysaccharide (β-1,3-), laminarin polysaccharide (β-1,3-1,6-), yeast dextran (β-1,3-1,6-), lichen polysaccharide (β-1,3-1,4-), and sodium carboxymethyl cellulose (CMC, β-1,4-) were prepared into 4% (w / v) solutions or colloids using 50 mM citrate-disodium hydrogen phosphate buffer (pH 6.5). The results are shown in Table 3.

[0065] Table 3 Substrate specificity of SlGlc16aM2 The results showed that SlGlc16aM2 exhibits high specificity for β-1,3-glycosidic bonds and high activity for kelp and laminarin containing β-1,3-glycosidic bonds, while showing no hydrolytic activity for β-1,4-glycosidic bonds, proving that its cleavage mode is endo-glucanase.

[0066] Example 4: Application of SlGlc16aM2 in the preparation of β-glucan oligosaccharides Following the reaction system of Example 3.1, using 4% guarana polysaccharide as the substrate, 50 μL of SlGlc16aM2 enzyme solution (approximately 5 mg / mL) was reacted at 65°C and pH 6.5 for 4 h. Samples were taken at 0, 15, 30, 60, 120, and 240 min, and after inactivation in a boiling water bath, they were analyzed by thin-layer chromatography (TLC).

[0067] TLC conditions: Spot 2 μL of sample onto a silica gel plate and develop twice in a developing buffer of n-butanol, acetic acid, and water (2:1:1, v / v / v). After development, dry the silica gel plate and immerse it in a methanol solution containing 5% sulfuric acid (5:95, v / v) for color development. After drying, heat at 130℃ for further color development. Use glucose and oligosaccharide standards with different degrees of polymerization as controls, and compare Rf values ​​to determine the product composition.

[0068] TLC results are as follows Figure 7 As shown, the main product of hydrolysis of SlGlc16aM2 with polysaccharides is β-glucan oligosaccharide with a degree of polymerization of 2-6, indicating that this mutant can be used efficiently for the enzymatic preparation of β-glucan oligosaccharides.

[0069] The specific details of SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, and SEQ ID NO.4 mentioned above are as follows.

[0070] SEQ ID NO.1 (wild-type β-1,3-glucanase): AEETQGEPSI EQEGWNLVWS DEFDGNSLDP SKWRHDIGNG QPNLPGWGNE ELQYYSDDDPK 60 NVRVENGELI IEAHQESVSD QYGTYGYTSG KVLTEGRFSQ TYGRFEARMR LPAGQGFWPA 120 FWMMPENDQY GGWAASGEID IMENAGGTPN KVGGAIHYGG PWPENQFQAG DYYFPAGTDA 180 TGYHEYAVEW EPGEIRWYVD GNHYQTINDW YSTGGSYPAP FDQDFHLILN LAVGGWYGGN 240 PDGSTPFPSS MAVDYVRVYE R 261 SEQ ID NO.2 (Gene for wild-type β-1,3-glucanase): gcggaagaaa cccagggcga accgagcatt gaacaggaag gctggaacct ggtgtggagc 60 gatgaatttg acggcaacag cctggatccg agcaaatggc gccatgatat tggcaacggc 120 cagccgaacc tgccgggctg gggtaatgaa gaactgcagt attacagcga tgatccgaag 180 aacgtgcgcg tggaaaacgg cgaactgatt attgaagcgc atcaggaaag cgtgagcgat 240 cagtatggca cctatggcta taccagcggc aaagtgctga ccgaaggccg ctttagccag 300 acctatggcc gctttgaagc gcgcatgcgc ttaccggcgg gtcaaggttt ttggccggcg 360 ttttggatga tgccggaaaa cgatcagtat ggcggctggg cggcgagcgg cgaaattgat 420 attatggaaa acgcgggcgg caccccgaac aaagtgggcg gcgcaattca ttatggtggt 480 ccgtggccgg aaaaccagtt tcaggcgggc gactattatt ttccggcggg caccgatgcg 540 accggctatc atgaatatgc ggtggaatgg gaaccgggcg aaattcgctg gtatgtggat 600 ggcaaccatt atcagaccat taacgattgg tatagcaccg gcggcagcta tccggcgccg 660 ttcgaccagg attttcatct gattctgaac ctggcggtgg gcggctggta tggcggcaac 720 ccagatggtt ctactccatt tccgagcagc atggcggtgg attatgtgcg cgtgtatgaa 780 cgctaa 786 SEQ ID NO.3 (β-1,3-glucanase mutant SlGlc16aM2): AEETQGEPSI EQEGWNLVWS DEFDGNSLDP SKWRHDIGNG QPNLPGWGNE ELQYYSDDPK 60 NVRVENGELI IEAHQESVSD DYGTYGYTSG KVLTEGRFSQ TYGRFEARMR LPAGQGFWPA 120 FWMMPENDQY GGWAASGEID IMENAGGTPN KVGGAIHYGG PWPENQFQAG DYYFPAGTDA 180 TGYHEYAVEW EPGEIRWYVD GNLYQTINDW YSTGGSYPAP FDQDFHLILN LAVGGWYGGN 240 PDGSTPFPSS MAVDYVRVYE R 261 SEQ ID NO.4 (Gene of β-1,3-glucanase mutant SlGlc16aM2): gcggaagaaa cccagggcga accgagcatt gaacaggaag gctggaacct ggtgtggagc 60 gatgaatttg acggcaacag cctggatccg agcaaatggc gccatgatat tggcaacggc 120 cagccgaacc tgccgggctg gggtaatgaa gaactgcagt attacagcga tgatccgaag 180 aacgtgcgcg tggaaaacgg cgaactgatt attgaagcgc atcaggaaag cgtgagcgat 240 gactatggca cctatggcta taccagcggc aaagtgctga ccgaaggccg ctttagccag 300 acctatggcc gctttgaagc gcgcatgcgc ttaccggcgg gtcaaggttt ttggccggcg 360 ttttggatga tgccggaaaa cgatcagtat ggcggctggg cggcgagcgg cgaaattgat 420 attatggaaa acgcgggcgg caccccgaac aaagtgggcg gcgcaattca ttatggtggt 480 ccgtggccgg aaaaccagtt tcaggcgggc gactattatt ttccggcggg caccgatgcg 540 accggctatc atgaatatgc ggtggaatgg gaaccgggcg aaattcgctg gtatgtggat 600 ggcaaccttt atcagaccat taacgattgg tatagcaccg gcggcagcta tccggcgccg 660 ttcgaccagg attttcatct gattctgaac ctggcggtgg gcggctggta tggcggcaac 720 ccagatggtt ctactccatt tccgagcagc atggcggtgg attatgtgcg cgtgtatgaa 780 cgctaa 786 The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.

Claims

1. A β-1,3-glucanase mutant, characterized in that, The β-1,3-glucanase mutant was obtained by mutating histidine at position 203 to leucine and glutamine at position 81 to aspartic acid, as shown in SEQ ID NO.1 of the wild-type β-1,3-glucanase, with the amino acid sequence shown in SEQ ID NO.

3.

2. An isolated nucleic acid, characterized in that, The nucleic acid is a DNA molecule encoding the β-1,3-glucanase mutant as described in claim 1.

3. The isolated nucleic acid according to claim 2, characterized in that, The nucleotide sequence of the DNA molecule is shown in SEQ ID NO.

4.

4. A recombinant expression vector, characterized in that, Includes the nucleic acid as described in any one of claims 2 or 3.

5. A recombinant expression transformant, characterized in that, Includes the recombinant expression vector as described in claim 4.

6. The recombinant expression transformant according to claim 5, characterized in that, The host cell for the recombinant expression transformant is Escherichia coli.

7. A β-1,3-glucanase catalyst, characterized in that, The β-1,3-glucanase catalyst comprises any of the following forms: (1) Cultivate the recombinant expression transformant according to claim 5, and isolate the transformant cells containing the β-1,3-glucanase mutant according to claim 1; (2) Cultivate the recombinant expression transformant according to claim 5, and separate the crude enzyme solution containing the β-1,3-glucanase mutant according to claim 1; (3) Cultivate the recombinant expression transformant according to claim 5, separate the crude enzyme solution containing the β-1,3-glucanase mutant according to claim 1, and freeze-dry the crude enzyme powder obtained; (4) Cultivate the recombinant expression transformant according to claim 5, separate the crude enzyme solution containing the β-1,3-glucanase mutant according to claim 1, and purify the obtained pure enzyme solution.

8. A method for preparing the β-1,3-glucanase mutant as described in claim 1, characterized in that, Includes the following steps: S1. Providing a DNA molecule encoding the β-1,3-glucanase mutant of claim 1; S2. The DNA molecule is cloned into an expression vector to construct a recombinant expression vector; S3. Transform the recombinant expression vector into host cells to obtain recombinant engineered bacteria; S4. Cultivate the recombinant engineered bacteria, induce expression, and collect and purify the β-1,3-glucanase mutant.

9. The use of a β-1,3-glucanase mutant as described in claim 1 or a β-1,3-glucanase catalyst as described in claim 7 in the degradation of β-1,3-glucan to prepare β-glucan oligosaccharides, characterized in that, The β-1,3-glucan includes kelp polysaccharide and / or laminarin polysaccharide.

10. The application according to claim 9, characterized in that, When the β-1,3-glucan is selected as a kerogen polysaccharide, the β-glucan oligosaccharide is a β-glucan oligosaccharide with a degree of polymerization of 2-6.

Citation Information

Patent Citations

  • Endo-beta-1, 3-glucanase mutant with improved enzyme activity and thermal stability

    CN120505298A